Page last updated: 2024-09-04

pomalidomide and Diffuse Large B-Cell Lymphoma

pomalidomide has been researched along with Diffuse Large B-Cell Lymphoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Batchelor, TT; Grommes, C; Nayak, L; Tun, HW	1
Amantangelo, MD; Barnes, L; Bjorklund, C; Breider, M; Cai, T; Chiu, H; Chopra, R; Couto, S; Daniel, TO; Fontanillo, C; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Khambatta, G; Klippel, A; Kosek, J; Lopez-Girona, A; Lu, G; Man, HW; Narla, RK; Pourdehnad, M; Raymon, H; Rychak, E; Schafer, PH; Thakurta, A; Trotter, M; Waldman, M; Wang, M	1

Reviews

1 review(s) available for pomalidomide and Diffuse Large B-Cell Lymphoma

Article	Year
Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape	2019

Article

Year

Introduction of novel agents in the treatment of primary CNS lymphoma.

Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3

Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape

2019

Trials

1 trial(s) available for pomalidomide and Diffuse Large B-Cell Lymphoma

Article	Year
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood, 2015, Aug-06, Volume: 126, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interferon Regulatory Factor-7; Interferons; Lenalidomide; Lentivirus; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Molecular Mimicry; Peptide Hydrolases; Piperidones; Proteolysis; Quinazolinones; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thalidomide; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays	2015

Article

Year

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

Blood, 2015, Aug-06, Volume: 126, Issue:6

Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interferon Regulatory Factor-7; Interferons; Lenalidomide; Lentivirus; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Molecular Mimicry; Peptide Hydrolases; Piperidones; Proteolysis; Quinazolinones; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thalidomide; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays

2015